Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《The Chinese Journal of Clinical Pharmacology》 2017-16
Add to Favorite Get Latest Update

Advances of the clinical application of cariprazine,a novel atypical antipsychotic drug

DONG Xiao-di;ZHAI Jin-guo;ZHAO Jing-ping;School of Mental Health,Jining Medical University;Institute of Mental Health, the Second Xiangya Hospital of Central South University;  
Cariprazine,a potent dopamine D_3 and D_2 receptor partial agonist with preferential binding to D_3 receptors,is approved by the US Food and Drug Administration( FDA) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in September 2015. A large number of clinical researches have confirmed that cariprazine has good efficacy,safety and tolerability in the treatment of schizophrenia or bipolar I disorder in adults. The aim of this article is to provide an up-to-date review about the mechanism of action,pharmacokinetics,drug-drug interaction,clinical application,safety and tolerance of cariprazine.
【Key Words】: cariprazine schizophrenia bipolar disorder atypical antipsychotic drug tolerance
【Fund】: 山东省医药卫生科技发展计划基金资助项目(2015WS0417);; 山东省自然科学基金资助项目(ZR2012HM065)
【CateGory Index】: R971
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
Similar Journals
> China Food Safety Magazine
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved